Investigation of thiazolidinedione derivatives for anti-diabetic screening: synthesis, in silico analysis, and in vivo evaluation

Gourav Trivedi; Prabhat Kumar Das; Nilesh  Mandloi; Bhoopendra  Patidar; Aman  Karma

doi:10.69857/joapr.v13i5.1412

Authors

Gourav Trivedi Department of Pharmaceutical Chemistry, GRY Institute of Pharmacy, Borawan, Kasrawad, Madhya Pradesh-451228, India
Prabhat Kumar Das Department of Pharmacology, GRY Institute of Pharmacy, Borawan, Kasrawad, Madhya Pradesh-451228, India
Nilesh Mandloi Department of Pharmaceutical Chemistry, GRY Institute of Pharmacy, Borawan, Kasrawad, Madhya Pradesh-451228, India
Bhoopendra Patidar Department of Pharmaceutical Chemistry, GRY Institute of Pharmacy, Borawan, Kasrawad, Madhya Pradesh-451228, India
Aman Karma Department of Pharmaceutical Chemistry, GRY Institute of Pharmacy, Borawan, Kasrawad, Madhya Pradesh-451228, India

DOI:

https://doi.org/10.69857/joapr.v13i5.1412

Keywords:

Anti-diabetics, In-silico study, Molecular design, Docking, thiazolidine-2, 4-dione

Abstract

Background: Diabetics possess inadequate amounts of insulin to control high glucose levels. Current WHO research estimates that 382 million people have diabetes mellitus, and by 2035, 592 million will. Thiazolidinedione, a physiologically active heterocyclic molecule, including thiazolidine-2,4-dione, is being studied for its anti-diabetic action. Thiazolidinediones, a class of hypoglycaemic drugs used to treat noninsulin-dependent diabetes, were first discovered as insulin-sensitive tissue stimulators. Methodology: In-silico applications like Lipinski's rule of five and Molinspiration evaluate physicochemical characteristics, and Molegro Virtual Docker docks molecules. Additionally, compounds are screened in vivo using alloxan as a diabetes inducer and pioglitazone as a comparator medication. Result and Discussion: Docking results determine the interactions of derivatives with 5U5L's active site (H2, H3, H5, H7, H9, and H14). Compound H3 interacts with Cys285, Tyr327, Ser289, His323, and Ala278, whereas compound H14 involves Ser289, Leu353, Phe360, Cys285, and Tyr473 with the PPAR-γ receptor, yielding docking scores of -128.341 and -129.766, respectively, and an RMSD value of 2.55 Å. Docking results showed anti-diabetic effects for H3 and H14. In animal screening, both compounds demonstrated efficacy against alloxan-induced diabetes models, supporting their computational findings. Conclusion: Pioglitazone interacts with hydrogen bonds involving Ser342, Tyr473, Ser289, Glu291, and Leu228 with a docking score of -118.485, while its co-crystal ligand interacts with Tyr327 and Tyr473 with -121.439. This work demonstrates that the thiazolidinedione pharmacophore is crucial for the discovery of anti-diabetic drugs. Both compounds showed significant anti-diabetic effectiveness in computational and in vivo screening. Thus, more research could prove the compound's anti-diabetic properties.

Downloads

Download data is not yet available.

References

Yameny A. Diabetes Mellitus Overview. Journal of Bioscience and Applied Research, 10(3), 641-645 (2024) https://doi.org/10.21608/jbaar.2024.382794.

Dilworth L, Facey A, Omoruyi F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. IJMS, 22, 7644 (2021) https://doi.org/10.3390/ijms22147644

Popoviciu MS, Paduraru L, Nutas RM, Ujoc AM, Yahya G, Metwally K, Cavalu S. Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities. Int J Mol Sci, 24, 12676 (2023) https://doi.org/10.3390/ijms241612676

Shintani H,Shintani T. Effects of antidiabetic drugs that cause glucose excretion directly from the body on mortality. Medicine in Drug Discovery, 8(1), 10062 (2020) https://doi.org/10.1016/j.medidd.2020.100062.

Vishwakarma A, Biswas V, Hasan F, Asma P, Sharma D. Diabetes mellitus: An updated overview and role of medicinal plants in modern treatment. Innovative Medicines & Omics, 2(2), 20-35 (2025) https://doi.org/10.36922/imo.7520.

Ibeyaima A, Loying R, Manna P.Prediction of the toxicity, bioavailability, pharmacokinetics, and Lipinski rule of 5 in the antidiabetic compounds: A computer-based investigation. InxxSilico Research in Biomedicine, 1-17 (2025) https://doi.org/10.1016/j.insi.2025.100026.

Basak S, Murmu A, Matore B, Roy P, Singh J. Thiazolidinedione an auspicious scaffold as PPAR-γ agonist: its possible mechanism to Manoeuvre against insulin-resistant diabetes mellitus.European Journal of Medicinal Chemistry Reports, 11(1), 1-17 (2024) https://doi.org/10.1016/j.ejmcr.2024.100160

Nath A, Kumer A. Investigating the binding affinity, molecular dynamics and ADMET properties of 2,3-dihydrobenzofuran derivatives as an inhibitor of fungi, bacteria, and virus proteins.Beni-Suef University Journal of Basic and Applied Sciences, 10(36), 1-13 (2021) https://doi.org/10.1186/s43088-021-00117-8.

Ghani S, Khan N, Sable H, Yao F, Muhammad S. Computational techniques for enhancing PK/PD modeling and simulation and ADMET prediction.Computational Methods in Medicinal Chemistry,Pharmacologyand Toxicology,153-174 (2025) https://doi.org/10.1016/B978-0-443-33024-7.00001-1.

Kumar KS, Rao AL. Design Synthesis Hypoglycemic Activity and Molecular Docking Studies of 3-substituted-5- [(furan-2-yl)-methylene]-thiazolidine-2,4-dione Derivatives.Indian Journal of Pharmaceutical Education and Research, 55(1), 2-4 (2021) https://doi.org/10.5530/ijper.55.1.30.

Loncaric M, Strelec I. Green Synthesis of Thiazolidine-2,4-dione Derivatives and Their Lipoxygenase Inhibition Activity with QSAR and Molecular Docking Studies.Frontiers in Chemistry, 10, 2-7 (2022) https://doi.org/10.3389/fchem.2022.912822.

Bacha MM, Nadeem H, Zaib S, Sarwar S, Imran A, Rahman SU, Ali HS, Arif M, Iqbal J. Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies. BMC Chem 15, 28 (2021) https://doi.org/10.1186/s13065-021-00756-z.

Lončarić M, Strelec I, Pavić V, Rastija V, Karnaš M, Molnar M. Green Synthesis of Thiazolidine-2,4-dione Derivatives and Their Lipoxygenase Inhibition Activity with QSAR and Molecular Docking Studies. Frontiers in Chemistry, 10(1), 1-15 (2022) https://doi.org/10.3389/fchem2022.912822

Lipinski CA. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced Drug Delivery Reviews, 101, 34–41 (2016) https://doi.org/10.1016/j.addr.2016.04.029.

Kumar H, Deep A, Marwaha R. Design synthesis in silico studies, and biological evaluation of 5-((E)-4-((E)-(substituted aryl/alkyl) methyl) benzylidene) thiazolidine-2,4-dione derivatives. BMC Chemistry, 14(25), 1-15 (2020) https://doi.org/10.1186/s13065-020-00678-2.

Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key Topics in Molecular Docking for Drug Design. Int J Mol Sci, 20, 4574 (2019) https://doi.org/10.3390/ijms20184574.

Trotsko N, Golus J, Kazimierczak P, Paneth A, Przekora A, Ginalska G, Wujec M. Design, synthesis and antimycobacterial activity of thiazolidine-2,4-dione-based thiosemicarbazone derivatives. Bioorg. Chem., 97, 103676 (2020) https://doi.org/10.1016/J.BIOORG.2020.103676.

Harikrishnan N, Geetha B. Insilico analysis and molecular docking studies of novel thiazolidinediones derivatives against ppar-y. Rasayan J. Chem., 15(2), 1419-1426 (2022) https://doi.org/10.31788/RJC.2021.1526797.

Goossens K, Tricarico G, Hofmans J, Dréanic, Stephane C, Lenselink E.ChemProp multi-task models for predicting ADME properties in the Polaris challenge.Theoretical and Computational Chemistry, 1-30 (2025) https://doi.org/10.26434/chemrxiv-2025-q12vhO.

Gupta S, Jha S, Rani S, Arora P, Kumar S. Medicinal Perspective of 2,4-ThiazolidinedionesDerivatives: An Insight into Recent Advancements.Chemistry Open, 13, 1-30 (2024) https://doi.org/10.1002/open.202400147.

Ansari B, Khan H. Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2,4-Dione Derivatives. Hindawi Journal of Chemistry, 11, 1-11 (2023) https://doi.org/10.1155/2023/9462176.

Sever B, Altıntop MD. A new series of 2, 4-thiazolidinediones endowed with potent aldose reductase inhibitory activity.Open Chemistry, 19, 347–357 (2021) https://doi.org/10.1515/chem-2021-0032.

Patel S, Sen A, Dash D, Sadhu P, Kumari M, Baile S. Synthesis, Characterization and Biological Evaluation of Thiazolidinedione Derivative as Novel Anti diabetic Agents.Journal of Pharmaceutical Research International, 33(35A), 123-135 (2021) https://doi.org/10.9734/JPRI/2021/v33i35A31881

Kumar H, Agarwal N,Gupta M, Deep A, Chopra H, Mohammed M, Roy A, Talha E, Mohanta Y, Marwaha R.Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant and Hypoglycemic Agents. Molecules, 27(19), 1-40 (2022) https://doi.org/10.3390/molecules27196763.

Patil V, Upadhyay N, Tilekar K, Joshi H. Hypoglycemic and Hypolipidemic Swords: Synthesis and In-vivo Biological Assessment of 5-benzylidene-2,4-thiazolidinediones, Iranian Journal of Pharmaceutical Research, 20(4),188-201 (2021) https://doi.org/10.22037/ijpr.2021.114969.15131.

Shehzad MT, Imran A. Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors. RSC Adv., 11, 17259–17282 (2021) https://doi.org/10.1039/d1ra01716k.

Mendoza E, Yelzyn G, Josué M, Cristian M, Blanca C, Emanuel H, Gloria I, Oscar P, Gabriel N. Design, Synthesis, and In Silico Multitarget Pharmacological Simulations of Acid Bioisosteres with a Validated In Vivo Antihyperglycemic Effect.Molecules, 26(799), 1-19 (2021) https://doi.org/10.3390/molecules26040799.

Ottana R, Paoli P. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complication Molecules, 26, 330 (2021) https://doi.org/10.3390/molecules26020330.

Vikhe S, Sukhadhane P, Vikhe R, Bornare SL, Dhavane SS. Antidiabetic effects of Semecarpus anacardium leaf extracts in streptozotocin-induced diabetes in rats. J. Appl. Pharm. Res., 12, 144–58 (2024) https://doi.org/10.69857/joapr.v12i6.736.

Belgin S, Mehlika D, Yeliz D, Cüneyt T, Kaan Ö, Gülşen A, Şükrü B, Ahmet Ö. A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity.Open Chemistry, 19, 347-357 (2021) https://doi.org/10.1515/chem-2021-0032.

Muhammad T, Aqeel I, Abdul H, Mariya R, Marium B, Maliha U, Asnuzilawati A, Shafia I, Habsah M, Muhammad N, Zahid S, Jamshed I. Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors.RSC Adv.,11(1),17259-17282 (2021) https://doi.org/10.1039/d1ra01716k.

Faruk J. Sterol Constituents of Sea Fan, as Potential Candidates of MPro Protein SARSCoV-2 Inhibitor: in silico.Indonesian Journal of Chemical Research, 9(3), 185-196 (2022) https://doi.org/10.30598//ijcr.

Chiarelli F, Di Marzio D. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag, 4, 297-304 (2008) https://doi.org/10.2147/vhrm.s993.

Naim MJ, Alam MJ, Ahmad S, Nawaz F, Shrivastava N, Sahu M, Alam O. Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship. Eur J Med Chem 129, 218-50 (2017) https://doi.org/10.1016/j.ejmech.2017.02.031.

Jinxi Z, Hu Z,Luo Y, Yinuo L, Wei L, Xiaohong D, Zhenzhong L, Jialing,Shengliang P. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment.Frontiers in Endocrinology, 1-17 (2024) https://doi.org/10.3389/fendo.2023.1265372.

Sameeh MY, Khowdiary MM. Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation.Molecules, 27, 830 (2022) https://doi.org/10.3390/molecules27030830.